Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study

Table 4 Preferred therapeutic regimens of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in Brazil

Synthetic DMARD Regimen^a	N (%)
Methotrexate monotherapy	154 (13.7)
Methotrexate + corticosteroid	135 (12.0)
Methotrexate + leflunomide	95 (8.4)
Methotrexate + leflunomide + corticosteroid	55 (4.9)
Leflunomide monotherapy	52 (4.6)
Methotrexate + antimalarial (hydroxichloroquine or chloroquine)	31 (2.8)
Leflunomide + corticosteroid	30 (2.7)
Antimalarial (hydroxichloroquine or chloroquine monotherapy)	17 (1.5)
Other^b	140 (12.4)

^a NSAIDs allowed for pain relief on an as-needed basis. ^b All other regimens of conventional synthetic DMARD whether in monotherapy or combination (none exceeding 1.5% of prescriptions individually)

ISSN: 2523-3106